

# Clinical trials of rosiglitazone and metformin

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

| Trial  | Treatments   | Patients                                 | Trials design and methods       |
|--|--|--|---------------------------------|
| <b>rosiglitazone and metformin vs placebo</b>  |  |  |                                 |
| <a href="#">CANOE , 2010</a><br>[NCT00116932]<br>n=103/104<br>follow-up: 3.9y (median) | rosiglitazone (2 mg) and metformin (500 mg) twice-daily<br>versus<br>placebo | patients with impaired glucose tolerance | Parallel groups<br>double-blind |

More details and results :

- prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q341>
- prevention for diabetes type 2 in people with impaired glucose tolerance at <http://www.trialresultscenter.org/go-Q416>

## References

### CANOE, 2010:

Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010 Jul 10;376:103-11 [[20605202](#)] [10.1016/S0140-6736\(10\)60746-5](#)

## 2 impaired fasting glucose

| Trial  | Treatments   | Patients                                 | Trials design and methods       |
|--|--|--|---------------------------------|
| <b>rosiglitazone and metformin vs placebo</b>  |  |  |                                 |
| <a href="#">CANOE , 2010</a><br>[NCT00116932]<br>n=103/104<br>follow-up: 3.9y (median) | rosiglitazone (2 mg) and metformin (500 mg) twice-daily<br>versus<br>placebo | patients with impaired glucose tolerance | Parallel groups<br>double-blind |

More details and results :

- prevention for impaired fasting glucose in all type of patients at <http://www.trialresultscenter.org/go-Q342>

## References

### CANOE, 2010:

Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. *Lancet* 2010 Jul 10;376:103-11 [20605202] [10.1016/S0140-6736\(10\)60746-5](https://doi.org/10.1016/S0140-6736(10)60746-5)

Entry terms: metformin, Metformin, Dimethylguanylguanidine, Dimethylbiguanidine, Glucophage,